<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24064973</article-id><article-id pub-id-type="pmc">3817324</article-id><article-id pub-id-type="pii">bjc2013581</article-id><article-id pub-id-type="doi">10.1038/bjc.2013.581</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Comment on &#x02018;Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery <italic>vs</italic> radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)'</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nagano</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><aff id="aff1"><label>1</label><institution>Tokyo Women's Medical University, Medical Center East, Obstetrics and Gynecology</institution>, 2-1-10 Nishiogu, Arakawa-ku, Tokyo, <country>Japan</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>naganoog@dnh.twmu.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><day>29</day><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>09</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>10</month><year>2013</year></pub-date><volume>109</volume><issue>9</issue><fpage>2505</fpage><lpage>2505</lpage><permissions><copyright-statement>Copyright &#x000a9; 2013 Cancer Research UK</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Cancer Research UK</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</license-p></license></permissions></article-meta></front><body><p><bold>Sir,</bold></p><p>In <italic>British Journal of Cancer</italic>, volume 108, <xref ref-type="bibr" rid="bib1">Katsumata <italic>et al</italic> (2013</xref>) reported negative results of randomised controlled trial (RCT) of neoadjuvant chemotherapy (NACT) for IB2, IIA2, and IIB cervical cancer. They concluded that NACT did not improve overall survival, but reduced the number of patients who received postoperative radiotherapy. However, this comment seems to be a little bizarre. If they really wanted to determine whether NACT before radical surgery improves overall survival, they should not change the other factors, including postoperative therapy between both NACT and control groups, because their study was a superiority trial, not a non-inferiority one. Indeed, therapeutic role of NACT for cervical cancer and its possibility to reduce postoperative adjuvant therapy are quite distinct matters.</p><p>If adjuvant radiotherapy had been given equally to all of the cases regardless of the surgical findings, like the study by <xref ref-type="bibr" rid="bib2">Sardi <italic>et al</italic> (1997</xref>), the results might have been different.</p></body><back><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katsumata</surname><given-names>N</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Kuzuya</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Yasugi</surname><given-names>T</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name><name><surname>Kodama</surname><given-names>S</given-names></name><name><surname>Mizunoe</surname><given-names>T</given-names></name><name><surname>Hiura</surname><given-names>M</given-names></name><name><surname>Kasamatsu</surname><given-names>T</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Kamura</surname><given-names>T</given-names></name><collab>Japan Clinical Oncology Group</collab></person-group><year>2013</year><article-title>Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery <italic>vs</italic> radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102)</article-title><source>Br J Cancer</source><volume>108</volume><supplement>(10</supplement><fpage>1957</fpage><lpage>1963</lpage><pub-id pub-id-type="pmid">23640393</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardi</surname><given-names>JE</given-names></name><name><surname>Giaroli</surname><given-names>A</given-names></name><name><surname>Sananes</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>M</given-names></name><name><surname>Soderini</surname><given-names>A</given-names></name><name><surname>Bermudez</surname><given-names>A</given-names></name><name><surname>Snaidas</surname><given-names>L</given-names></name><name><surname>Vighi</surname><given-names>S</given-names></name><name><surname>Gomez Reuda</surname><given-names>N</given-names></name><name><surname>di Paola</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results</article-title><source>Gynecol Oncol</source><volume>67</volume><supplement>(1</supplement><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">9345358</pub-id></mixed-citation></ref></ref-list></back></article>